Abstract
The PTEN/MMAC1/TEP1 gene, located at 10q23.3, is a tumor suppressor gene responsible for the familial cancer syndromes Cowden disease and Bannayan-Zonana syndrome, and is commonly somatically mutated in several types of cancers. Mutations of the PTEN gene have been found in prostate cancer cell lines and LOH at 10q22-24 in prostate tumors have also been described with a high frequency. To determine the role of this gene in prostate tumorigenesis, we therefore analysed 22 primary tumors for loss of heterozygosity (LOH) within the 10q22-23 region such that tumors hemizygous at those loci may be examined for somatic PTEN mutations. Losses of heterozygosity of at least one locus was found in 12 (55%) of the 22 tumors DNAs. Among these, six tumors exhibited allele loss in the interval between D10S1765 and D10S541 wherein lies the PTEN gene. We searched the entire coding region of PTEN for somatic mutations in these six tumors. One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in one tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pesche, S., Latil, A., Muzeau, F. et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16, 2879–2883 (1998). https://doi.org/10.1038/sj.onc.1202081
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202081
Keywords
This article is cited by
-
Clinical implications of PTEN loss in prostate cancer
Nature Reviews Urology (2018)
-
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
BMC Medicine (2016)
-
Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer
Modern Pathology (2016)
-
Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia
Modern Pathology (2013)
-
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
BMC Medicine (2012)